A new generation of implantable “living pharmacies” is moving closer to reality, offering the potential to revolutionize treatment for chronic diseases. Scientists have developed a device, roughly the size of a folded stick of gum, that can continuously produce and deliver multiple therapeutic drugs inside the body, bypassing the necessitate for frequent injections or pills. The research, published this week in the journal Device, details a system that combines engineered cells with bioelectronics to create a self-contained, wireless drug factory.
The breakthrough addresses a major hurdle in cell-based therapies: keeping the therapeutic cells alive and functioning long enough to have a meaningful effect. The device, dubbed HOBIT (hybrid oxygenation bioelectronics system for implanted therapy), tackles this challenge by generating oxygen directly within the implant, providing the cells with the vital resource they need to survive and produce medication. This innovation could dramatically improve the lives of patients managing conditions like type 1 diabetes, HIV and metabolic disorders, offering a more convenient and potentially more effective treatment approach.
The study, led by a collaborative team from Northwestern University, Rice University, and Carnegie Mellon University, demonstrated the device’s ability to simultaneously produce three different biologics – an anti-HIV antibody, a GLP-1-like peptide for type 2 diabetes, and leptin, a hormone regulating appetite – in a small animal model. Researchers monitored drug levels in the animals’ bloodstreams for 30 days, finding sustained therapeutic levels with the oxygenated implants. The findings represent a significant step forward in the field of implantable bioelectronics and personalized medicine. The research is available online at Device.
Overcoming the Oxygen Barrier
Implantable cell therapies have long been hampered by a fundamental biological limitation: oxygen supply. When cells are encapsulated within an implant, they compete for limited oxygen, leading to cell death and reduced drug production. “The biggest challenge with these ‘living pharmacies’ has always been keeping the cells alive,” explains Jonathan Rivnay, co-principal investigator of the project and a professor of biomedical engineering at Northwestern’s McCormick School of Engineering. “Cells need oxygen to function, and it’s difficult to deliver enough oxygen to cells packed inside an implant.”
The HOBIT system directly addresses this issue with a miniature oxygen generator. This technology builds upon previous work by Rivnay and his team, who in 2023 demonstrated a tiny electrochemical device capable of splitting water molecules to produce oxygen. Northwestern News reported on that earlier breakthrough, which showed improved cell survival in implanted therapeutic cells. The new iteration integrates this oxygen-generation technology into a fully implantable, wireless system, creating a self-sustaining environment for the therapeutic cells.
HOBIT consists of three key components: a cell chamber housing the engineered cells, a miniature oxygen generator, and integrated electronics with a battery to regulate oxygen production and enable wireless communication. The device’s design not only provides a constant oxygen supply but similarly shields the cells from the body’s immune system, further enhancing their viability. Rivnay notes that cell densities within HOBIT were approximately six times higher than those achieved with conventional, unoxygenated encapsulation methods.
Sustained Drug Delivery in Animal Models
To validate the HOBIT system, the researchers engineered cells to produce three different biologics, each with a distinct half-life – the time it takes for the drug concentration in the body to decrease by half. They then implanted the devices under the skin of rats and monitored blood levels of the produced drugs over a 30-day period.
The results were compelling. Animals receiving the oxygenated implants maintained sustained levels of all three biologics throughout the study. In contrast, animals with devices lacking oxygenation saw the biologics with shorter half-lives become undetectable within seven days, and even those with longer half-lives showed declining levels over time. At the end of the testing period, approximately 65% of the cells in the oxygenated devices remained viable, compared to only 20% in the control devices.
These findings demonstrate the HOBIT system’s ability to not only keep cells alive but also to maintain stable, therapeutic levels of multiple drugs simultaneously. This is particularly significant for conditions requiring complex treatment regimens involving multiple medications with varying durations of action.
Looking Ahead: Larger Trials and Expanded Applications
The research team, led by Rivnay, Omid Veiseh of Rice University, and Tzahi Cohen-Karni of Carnegie Mellon University, is now planning to test the technology in larger animal models. They are also exploring potential applications for a range of diseases, including therapies based on transplanted pancreatic cells for type 1 diabetes. “We’re beginning to witness how bioelectronics and cell therapy can work together in a single platform,” Rivnay said. “As these technologies continue to develop, devices like this could eventually act as programmable drug factories inside the body — delivering complex therapies in ways that simply aren’t possible today.”
The study was supported by grants from Breakthrough T1D (award number 3-SRA-2024-1564-S-B) and the U.S. Defense Advanced Research Projects Agency (award number FA8650-21-2-7119). Researchers anticipate that further development and clinical trials will be necessary before these implantable living pharmacies become widely available to patients. The next step involves scaling up production and conducting rigorous safety and efficacy testing in larger animal models, with the ultimate goal of initiating human clinical trials within the next few years.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share your thoughts on this exciting development in the comments below, and share this article with anyone who might be interested in the future of personalized medicine.
Keep reading
